← Back to Clinical Trials
Recruiting NCT05867706

NCT05867706 Caregiver Stress and Bereavement

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05867706
Status Recruiting
Phase
Sponsor University of Zurich
Condition Caregiver Burden
Study Type OBSERVATIONAL
Enrollment 150 participants
Start Date 2024-10-01
Primary Completion 2027-12-31

Trial Parameters

Condition Caregiver Burden
Sponsor University of Zurich
Study Type OBSERVATIONAL
Phase N/A
Enrollment 150
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-10-01
Completion 2027-12-31

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The death of a spouse is considered one of the most stressful and impactful life events and is associated with increased morbidity and premature mortality. Early identification of individuals who are most at risk for poor health outcomes following bereavement is an important aim of precision medicine and disease prevention initiatives. A better understanding of caregiver burden and bereavement-related distress and its implication for health is a clinically-relevant step toward the development of treatments that improve health outcomes in bereaved spouses. This study aims to map profiles of individual differences in short- and long-term adjustment to loss, according to psychological (e.g., depression, stress, grief severity) and biological markers (e.g., inflammation, cortisol) over time.

Eligibility Criteria

Inclusion Criteria: * Participant age ≥ 18 years * Caregiver or spouse of a patients suffering from a terminal illness (estimated life expectancy ≤ 6 months), * regarded as the patients primary caregiver (i.e., intimately involved in care of the patient since time of the diagnosis, looking after his/her daily needs, supervising the medications, bringing the patient to the hospital, staying with the patient during inpatient stay, and maintaining liaison with the hospital staff), * German as primary language * signed informed consent. Exclusion Criteria: * Significant visual or auditory problems, cognitive impairment, * morbid obesity (body mass index ≥40 kg/m2, * alcohol or drug abuse * active malignancy * severe illness (respiratory, heart, liver and renal failure) * major medical conditions involving the immune system (e.g., diabetes type 1 or 2, autoimmune and/ or inflammatory diseases including rheumatoid arthritis and ulcerative colitis, asthma, thyroid diseases) * severe hypertens

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology